Immunotherapy
Cancer treatment that trains the patient's own immune system to attack tumors.
Coverage of Immunotherapy is fading : 14 signals on the latest tracked day, down 12% from its three-week baseline of 16, across 4 domains (unchanged from a week ago). That makes it the #74 most-covered of the 274 concerns we track.
If Immunotherapy matters to your work, attention is draining away — the pace of news no longer demands a daily check.
What’s changed
5 of the last 7 tracked days ran below the three-week baseline — a sustained cooling, not a one-day dip.
- Foretinib triggers immunogenic cell death and enhances efficacy of anti-CD47 immunotherapy in colorectal cancer. · Neoplasia · 2026-08-01
- Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status · Clinical Colorectal Cancer · 2026-07-31
- CEUS with VEGFR2-targeted microbubbles for monitoring of early immunotherapy effects in a colorectal cancer model. · Cancer Imaging · 2026-07-31
- Reply to: “Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?” and “Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?” · Journal of Clinical Oncology · 2026-07-27
- IGHG1⁺ plasma cells define an NF-κB-driven inflammatory program that shapes T-cell immunity and immunotherapy response in colorectal cancer. · Transl Oncol · 2026-07-27
- Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope? · Journal of Clinical Oncology · 2026-07-26
What the reporting says
It shows up alongside Colorectal Cancer (196), MSI-H (39), KRAS (18), ctDNA (16), FDA (39), China (17), Merck (17), AI (14).
Two steps out: Egfr (through Colorectal Cancer, 39 shared stories on the weaker link); United States (through FDA, 39 shared stories on the weaker link); Eli Lilly (through FDA, 24 shared stories on the weaker link); CMS (through FDA, 23 shared stories on the weaker link).
Tracked since Dec 31, with coverage on 99 separate days — concentrated in Oncology and Pubmed Targeted.